Important Information

Electronic versions of the materials you are seeking to access are being made available on this webpage by Oasmia Pharmaceutical AB (publ) (“Oasmia”) in good faith and for information purposes only. These materials are not directed at or accessible by persons in the Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa or the United States. Please read this notice carefully—it applies to all persons who view this webpage. Please note that the information set out below may be altered or updated. You should read this message in full each time you visit the site.

Overseas Persons

Viewing the materials you seek to access may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to view such materials. Any persons who wish to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so.

In particular, unless otherwise determined by Oasmia and permitted by applicable law and regulation, it is not intended, subject to certain exceptions, that any offer mentioned in such materials (the “Offer”) would be made, or any documentation be sent, directly or indirectly, in or into, the Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa or the United States.

The materials on this webpage are not for distribution or transmission, directly or indirectly, in or into the Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa or the United States and does not constitute, or form part of, an offer to purchase, subscribe for, sell or exchange or the solicitation of an offer to purchase, subscribe for, sell or exchange any securities to any person in the Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa or the United States, nor the solicitation of any vote or approval in any such jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in the materials in any jurisdiction in contravention of applicable law (the “Restricted Jurisdictions”). The Offer is not being made, directly or indirectly, in or into the United States or any other Restricted Jurisdiction, or by use of the mails, or by any means or instrumentality (including, without limitation, facsimile transmission, telephone and the Internet) of interstate or foreign commerce, or of any facility of a national securities exchange, of the United States or any other Restricted Jurisdiction and the Offer cannot be accepted by any such use, means, instrumentality or facility or from within the United States or any other Restricted Jurisdiction. The Oasmia shares have not been, and will not be, registered under the US Securities Act of 1933, as amended (the “Securities Act”) and may not be transferred or offered for sale in the United States unless registered under the Securities Act or an exemption from such registration is available. No offering of Oasmias shares is being made in the United States.

If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

isputes arising from the issue prospectus, the offer and related legal matters shall be settled exclusively by Swedish Law and by a Swedish Court whereby the district court of Stockholm shall be of the first instance.

By accepting the terms above, you certify that you are not resident or physically present in Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa, USA or any other Restricted Jurisdiction.

I have read, understood and accept the above.

I ACCEPT                                                                         I DO NOT ACCEPT